Prevalence and Contributing Factors of Isoniazid Monoresistance and Multidrug-Resistant Tuberculosis in Almaty, Kazakhstan - Report - MDSpire

Prevalence and Contributing Factors of Isoniazid Monoresistance and Multidrug-Resistant Tuberculosis in Almaty, Kazakhstan

  • By

  • Juliana G. E. Bartels

  • Nurlan Takenov

  • Lyailya Chingissova

  • Anar Rakisheva

  • Ainur Eleusizova

  • Venera Bismilda

  • Lyazzat Yeraliyeva

  • Yanis Ben Amor

  • January 29, 2026

  • 0 min

Share

Clinical Report: Prevalence and Contributing Factors of Isoniazid Monoresistance

Overview

This study estimates the prevalence of isoniazid monoresistance and multidrug-resistant tuberculosis (MDR-TB) in Almaty, Kazakhstan, highlighting significant rates of drug resistance. The findings underscore the urgent need for improved diagnostic and treatment strategies in high-burden regions.

Background

Drug-resistant tuberculosis (DR-TB) is a significant global health challenge, complicating treatment and increasing costs. In Kazakhstan, a country with a high burden of MDR-TB, understanding the prevalence of isoniazid-resistant TB (Hr-TB) is critical for effective public health interventions. This study fills a crucial knowledge gap regarding Hr-TB rates in Almaty, which is essential for reducing morbidity and mortality associated with DR-TB.

Data Highlights

No numerical data was provided in the source material.

Key Findings

  • High prevalence of isoniazid monoresistance (Hr-TB) and MDR-TB was observed in Almaty.
  • Previous treatment history significantly correlated with higher rates of MDR-TB.
  • Demographic factors such as age and gender were analyzed for their association with drug resistance.
  • Effective surveillance and diagnostic strategies are necessary to address the rising rates of drug resistance.
  • Improved public health policies are needed to manage and treat DR-TB effectively.

Clinical Implications

Healthcare providers in high-burden regions must prioritize accurate diagnosis of Hr-TB to align treatment strategies with current guidelines. Enhanced surveillance and public health initiatives are essential to mitigate the spread of drug-resistant strains.

Conclusion

The findings from this study highlight the critical need for improved diagnostic capabilities and treatment protocols in managing drug-resistant tuberculosis in Kazakhstan. Addressing these issues is vital for controlling the DR-TB epidemic.

References

  1. Open Forum Infectious Diseases, 2022 -- Evaluation of Two Diagnostic Tools for Identifying Mycobacterium tuberculosis and Drug Resistance in Almaty, Kazakhstan
  2. Open Forum Infectious Diseases, 2022 -- Extensive Endemic Transmission of Multidrug-Resistant Mycobacterium tuberculosis in Bhutan: A Retrospective Genomic-Epidemiological Study
  3. Open Forum Infectious Diseases, 2022 -- Evaluating the Diagnostic Precision and Clinical Relevance of Xpert MTB/XDR for Rifampicin-Resistant Tuberculosis Patients in Georgia
  4. Global tuberculosis report 2025 -- WHO
  5. WHO announces landmark changes in treatment of drug-resistant tuberculosis, 2025
  6. Open Forum Infectious Diseases — Challenges Associated with the MTB/RIF Assay: A Review of Four Clinical Cases
  7. WHO Global TB Report 2025
  8. ICAP at Columbia University - Oral Regimens for Rifampin-Resistant Tuberculosis
  9. WHO announces landmark changes in treatment of drug-resistant tuberculosis

Original Source(s)

Related Content